Norwegian University of Science and Technology

ntnu.edu

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

488

Active

66

Phase 3

20

Total enrollment

145,759

Pipeline matrix

Showing 31 of 31 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Botulinum Toxin Type A5
ExPlas1
Octaplasma1
Saline1
Atezolizumab1
Blood samples2
Ibuprofen3
Candesartan2
Venlafaxine1
Stool samples1
Quetiapine1
Valsartan1
Ramipril1
Gabapentin1
Chlorprothixene1
Multidisciplinary treatment1
Treatment as usual1
Fecal samples1
Enalapril1
Apixaban1
Paracetamol1
Metoprolol1
Escitalopram1
Fluoxetine1
Losartan1
Irbesartan1
Lercanidipine1
Hydrochlorothiazide1
Amlodipine1
Lamotrigine1
Buprenorphine1

Next readouts

  • 2024-04-01
  • 2024-11-10
  • 2025-09
  • 2026-05
  • 2026-10
  • 2026-10
  • 2026-10
  • 2026-10
  • 2026-10
  • 2026-10

Top conditions

  • Obesity, Morbid31
  • Obesity30
  • Stroke10
  • Mental Disorders9
  • Cardiovascular Diseases9
  • Pain8
  • Cancer8
  • Polycystic Ovary Syndrome8

Frequently asked questions about Norwegian University of Science and Technology

How many clinical trials does Norwegian University of Science and Technology have on ClinicalTrials.gov?
Norwegian University of Science and Technology is listed as the lead sponsor on 488 clinical trials in ClinicalTrials.gov, 66 of which are currently active (recruiting, enrolling, or ongoing).
How many of Norwegian University of Science and Technology's trials are in Phase 3?
20 of Norwegian University of Science and Technology's trials are in Phase 3, spread across 31 active drug programs.
What therapeutic areas does Norwegian University of Science and Technology focus on?
Norwegian University of Science and Technology's most-studied conditions on ClinicalTrials.gov are Obesity, Morbid, Obesity, Stroke, Mental Disorders, Cardiovascular Diseases.
When are Norwegian University of Science and Technology's next clinical trial readouts?
Norwegian University of Science and Technology has 10 upcoming primary-completion readouts tracked here; the soonest is “Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer”, expected around 2024-04-01.